CAJ | 학술논문

目的：观察替吉奥单药治疗晚期非小细胞肺癌(non-small cell lung cancer，NSCLC)的近期疗效及不良反应。方法45例经病理组织学确诊的晚期NSCLC患者,按简单随机方法分为观察组22例和对照组23例。观察组采用替吉奥胶囊单药化疗，80 mg·m－2·d－1，分早晚2次服用，连用28 d，休息2周，6周为一周期，同时行常规支持治疗；对照组接受中成药（艾迪注射液）抗肿瘤及最佳支持治疗。2周期后评价近期疗效和不良反应。结果观察组疾病控制率为54.55%(12/22)，明显高于对照组的21.74%(5/23)(P＜0.05)。观察组主要不良反应有白细胞减少、血小板减少、贫血、恶心呕吐、口腔黏膜炎、腹泻，无Ⅳ级不良反应；对照组仅1例出现轻度恶心反应。结论替吉奥胶囊单药治疗晚期NSCLC有一定的疗效，不良反应可以耐受，安全性良好。
목적：관찰체길오단약치료만기비소세포폐암(non-small cell lung cancer，NSCLC)적근기료효급불량반응。방법45례경병리조직학학진적만기NSCLC환자,안간단수궤방법분위관찰조22례화대조조23례。관찰조채용체길오효낭단약화료，80 mg·m－2·d－1，분조만2차복용，련용28 d，휴식2주，6주위일주기，동시행상규지지치료；대조조접수중성약（애적주사액）항종류급최가지지치료。2주기후평개근기료효화불량반응。결과관찰조질병공제솔위54.55%(12/22)，명현고우대조조적21.74%(5/23)(P＜0.05)。관찰조주요불량반응유백세포감소、혈소판감소、빈혈、악심구토、구강점막염、복사，무Ⅳ급불량반응；대조조부1례출현경도악심반응。결론체길오효낭단약치료만기NSCLC유일정적료효，불량반응가이내수，안전성량호。
Objective To observe the short-term efficacy and adverse reactions of S-1 in the treatment of advanced non-small-cell lung cancer(NSCLC).Methods Forty-five patients with advanced NSCLC confirmed by histopathology were randomly divided into two groups. The observation group (n=22) was treated with S-1 80 mg·d-1 twice daily (morning and evening) for consecutive 28 days and was simultaneously given routine supportive treatment. Then the drug was discontinued for 2 weeks. Each treatment cycle was 6 weeks. The control group (n=23) was treated with Chinese patent medicine (Aidi-injection) and best supportive care. The short-term efficacy and adverse reactions were evaluated after 2 weeks. Results The disease control rate in observation group (54.55%,12/22) was significantly higher than that in control group (21.74%,5/23).The main adverse reactions included leucopenia, thrombocytopenia, anemia, nausea, vomiting, oral mucositis and diarrhea in observation group. No grade Ⅳ adverse reactions were found in observation group.Only 1 patient had mild nausea in control group. Conclusion The S-1 is an effective and safe treatment with acceptable toxicity in patients with advanced NSCLC.